Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non–small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials
Sumit Mahato, Shiv Mudgal, Harminder Singh, Seshadri Reddy Varikasuvu, Hansraj Kumar, Jameema Thankachan, Subodh Kumar · 2026
Read Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non–small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials by Sumit Mahato, Shiv Mudgal, Harminder Singh, Seshadri Reddy Varikasuvu, Hansraj Kumar, Jameema Thankachan, Subodh Kumar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13574751.txt.
Description
Sumit Mahato and co-authors compare three generations of targeted drugs for a form of lung cancer in a 2026 analysis. The cancer carries changes in a growth gene called EGFR, and pills that block that gene are the standard first treatment. With many pills on offer and few direct contests, the best first pick was unclear.
The team pooled randomized trials through a network method that links drugs compared in separate studies. Two newer drugs improved survival over first-generation pills. All newer drugs slowed cancer growth, with one posting the best score on that measure. Severe side effects did not differ clearly across the drugs. No single pill won on every measure, though one showed the steadiest overall profile.
Catalog record
| CREATOR | Sumit Mahato, Shiv Mudgal, Harminder Singh, Seshadri Reddy Varikasuvu, Hansraj Kumar, Jameema Thankachan, Subodh Kumar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |